[Neuroprotective therapy for amyotrophic lateral sclerosis (ALS)]

Area of Science:

• Neuroscience
• Neurology

Context:

• Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative disorder.
• Characterized by motor neuron degeneration, leading to muscle atrophy, weakness, and respiratory failure.
• Symptoms like dysphagia and dysarthria significantly impair daily activities and survival.

Purpose:

• To review recent advancements in understanding neuronal death in ALS.
• To explore therapeutic strategies targeting neuroprotection and disease course prolongation.
• To evaluate the efficacy of drugs such as riluzole in clinical trials.

Summary:

• Recent research into the mechanisms of neuronal death in ALS has spurred the development of neuroprotective drugs.
• Investigational therapies include glutamate excitotoxicity inhibitors, free radical scavengers (e.g., lecithinized superoxide dismutase), and neurotrophic factors.
• Riluzole demonstrated significant life-extending benefits in a US-Europe trial, but yielded inconclusive results in a Japanese nationwide study.

Impact:

• Highlights the potential of pharmacological interventions to modify ALS progression.
• Underscores the need for further research into population-specific treatment responses.
• Emphasizes the ongoing challenge of developing effective therapies for this intractable disease.